Frank D’Amelio to Step Down as Pfizer CFO
Frank D’Amelio is retiring as CFO of Pfizer soon after a fourteen-year tenure during which he performed vital roles in transformative transactions and the drugmaker’s response to the COVID-19 pandemic.
Pfizer said Wednesday it experienced begun an external lookup for D’Amelio’s successor and that he experienced agreed to continue to be with the firm through the process and serve in a consulting position through the transition.
Frank D’Amelio
In addition to his finance chief position, D’Amelio has served as executive vice president for world provide due to the fact he joined Pfizer in 2007.
“I want to thank Frank for his quite a few many years of assistance to Pfizer as CFO and for the impact he has experienced on the firm and the clients we serve,” CEO Albert Bourla said in a news launch.
“Frank has pushed a strategic eyesight for the company’s money good results, and he leaves Pfizer in a powerful posture for long term growth possessing been instrumental in our multi-year transformation to an market-top, science-primarily based biopharmaceutical firm,” he said.
As part of that transformation, D’Amelio oversaw the divestitures of Pfizer’s animal health and fitness, buyer health and fitness, and experienced products companies and the $sixty eight billion acquisition of Wyeth in 2009. For the duration of his tenure as CFO, Pfizer produced shut to $a hundred and fifty billion in marketplace cap growth.
Most recently, Pfizer said, he “helped tutorial the organization through 1 of its most challenging intervals as it worked to deal with the COVID-19 crisis.”
D’Amelio’s successor will be accountable for deploying the dollars that Pfizer is making from its COVID-19 vaccines. The firm is also searching for Food and drug administration emergency acceptance for a tablet to treat the virus.
Achievable utilizes of the vaccine dollars consist of acquisitions, partnerships, or share repurchases, in accordance to Damien Conover, an analyst at Morningstar. “It’s going to be a enormous windfall,” he informed The Wall Avenue Journal. “They’re going to have to execute genuinely well on redeploying that money.”
Right before joining Pfizer, D’Amelio acquired just about three many years of extensive functioning and money working experience at AT&T, Lucent Technologies, and Alcatel-Lucent. He begun his vocation in 1979 at Bell Labs.
